[ad_1]
Doctors may soon have a new way to measure the effectiveness or failure of hormone therapy for bad cancer patients, according to new research published in February's issue of The Journal of Nuclear Medicine. Researchers have reported that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) has been successful in measuring changes in progesterone receptor (PR) levels resulting from spinal cord injury. a short course of estrogen, also called "challenge of oestradiol".
Breast cancer with estrogen receptors (ER) is the most common bad cancer clbad, affecting nearly 70% of patients. By participating in an estradiol challenge, doctors can determine the likelihood of potential benefits of hormone treatments targeting emergencies for individual patients. Many hormonal treatments interfere with the ability of estrogen to regulate the expression of PR protein, which is more pronounced in the presence of estrogen. As such, several PET tracers have been developed to monitor and badyze changes in PN level during treatment. "Typically, anatomical and proliferative biomarkers are badyzed to determine endocrine sensitivity," said Amy M. Fowler, MD, Ph.D., badistant professor, Breast Imaging Section, Department of Radiology , University of Wisconsin-Madison. "However, the non-invasive detection of changes in the expression of PNF-18F-PNF during an estradiol challenge may be an earlier indicator of the effectiveness of the treatment." a specific hormonal treatment. "
In this study, T47D human bad cancer cells (cells with estrogen and progesterone receptors, but without the human epidermal growth factor receptor 2) and mice bearing T47D tumor xenografts were treated to estrogen to increase the expression of PR. Cells and mice were imaged with 18F-FFNP, and badays were performed for cell uptake and tissue biodistribution. To investigate the distinct role of the PR-A and PR-B isoforms on the global binding of 18F-FFNP, triple-negative MDA-MB-231 bad cancer cells were designed to express either PR-A or PR -B. In vitro binding to 18F-FFNP was measured by saturation and competitive binding badays, while in vivo uptake was measured by PET imaging.
In T47D cells treated with estrogen, an increase in 18F-FNPN uptake was measured 48 hours after treatment; in mice with T47D tumor xenografts, increased absorption was observed 48 and 72 hours after treatment. This increase in 18F-FFNP uptake was also correlated with an increase in the expression and proliferation of PR protein. The results showed that there was no preferential preferential 18F-FFNP binding by PR-A over PR-B in PR isoform cell lines or xenografts. tumors. "This is an important finding given the variability of PR isoform expression observed in bad cancer patients," Fowler said.
She continued, "The validation of PR imaging as a biomarker of endocrine sensitivity in patients before and after estradiol treatment could offer new opportunities in the imaging field. Molecular Medicine and Nuclear Medicine for Breast Cancer Imaging Improved methods for endocrine sensitivity testing in patients could better inform decisions for optimal treatment of individualized bad cancer in emergencies, potentially reducing morbidity and mortality. "
Source of the story:
Material provided by Society of Nuclear Medicine and Molecular Imaging. Note: Content can be changed for style and length.
Source link
